AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00768456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Local Infiltration with NaCl
Study NCT01834911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine withdrawal
Description: Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
Study NCT02819804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02819804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02819804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02819804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03060096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Anxiety/depression: High Intensity Stepped Care
Description: The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
Study NCT03060096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Anxiety/depression: Low Intensity Stepped care
Description: The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
Study NCT03060096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study.
Study NCT03591211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Training
Description: Eight-Section Brocades; participants were trained individually.
Study NCT03591211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
Study NCT01512238 — intervention group
Intervention type: OTHER
Intervention: Pharmaceutical care
Description: Information about medicine, sideeffect, adherence
Study NCT03330301 — intervention group
Intervention type: OTHER
Intervention: D-tect
Description: 1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on
Study NCT01821118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ponezumab
Description: Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
Study NCT01821118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (saline)- given via infusion total infusion time of 20 minutes
Study NCT02202941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin guided treatment
Description: Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
Study NCT02202941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
Study NCT02350140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging from beginning
Description: Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time.
Study NCT02350140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text messaging after 6 months of control
Description: After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
Study NCT02895893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Smart
Description: Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
Study NCT00439517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFOX + Cetuximab
Description: * Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks)~* Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~* Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21
Study NCT00439517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 + Cetuximab
Description: * Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16~* Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16
Study NCT02224560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
Study NCT02224560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT00988728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900435 (Org 25935)
Description: Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day).
Study NCT00988728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.
Study NCT00988728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.
Study NCT00988728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.
Study NCT00988728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day).
Study NCT02198378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA and paracetamol
Description: The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
Study NCT02198378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
Study NCT02566421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02566421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02566421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Therapy
Description: Receive treatment based on genomic sequencing
Study NCT02261701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
Study NCT02261701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post surgery shoulder lock
Description: Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
Study NCT00560001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD.2 Medication Dispenser
Description: For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
Study NCT00560001 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: MD.2 Medication Dispenser
Description: For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
Study NCT03254758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1.
Study NCT00272311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage
Study NCT00477386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4.
Study NCT02052388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Active Comparator
Study NCT02052388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Experimental Drug
Study NCT01308437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin (N or 70/30 with R)
Description: Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
Study NCT01308437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin® (N or 70/30 with R)
Description: Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
Study NCT04067817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine
Description: patient who was received the treatment of norepinephrine
Study NCT04067817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: patient who was received the treatment of phenylephrine
Study NCT02871934 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SLCO1B1 Genotype
Description: Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
Study NCT04000633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
Study NCT04000633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT00929695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: immunosuppressive drug
Study NCT00929695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: immunosuppressive drug
Study NCT00929695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: immunosuppressive drug
Study NCT00929695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: immunosuppressive drug
Study NCT00929695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00929695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT04616456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study NCT04616456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: verdiperstat targets microglial inflammation in the brain
Study NCT00318643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: intravesical administration
Study NCT00318643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: intravesical administration
Study NCT02778737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based intervention
Description: Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts.
Study NCT02778737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-based intervention
Description: Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts.
Study NCT04077216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Description: This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
Study NCT00855881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Description: tegafur-uracil 1 cap, bid for 1 year
Study NCT01736995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy
Study NCT01736995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Tx/Cognitive Behavioral Tx
Study NCT01736995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Study NCT02500797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02500797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02500797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02500797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03511937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage Health Warning Label
Description: Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
Study NCT03511937 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neutral Label
Description: Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
Study NCT04042948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
Study NCT01249079 — intervention group
Intervention type: OTHER
Intervention: No intervention would be provided in this research
Description: No intervention would be provided in this research,but need to draw blood
Study NCT04378543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ART352-L
Description: recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
Study NCT00357006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 100 mcg adjunctive transdermal estradiol
Study NCT00357006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 200 mcg adjunctive transdermal estradiol
Study NCT00357006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: adjunctive transdermal placebo
Study NCT03171961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online visit group
Description: subjects has online visit with dietitian every 2 weeks+diet
Study NCT03171961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic visit group
Description: Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
Study NCT03171961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-directed group
Description: self-directed group receives nutritional information via web and their energy needs for weight loss
Study NCT00981448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc acetate
Description: 50mg of elemental zinc to be administered 2 times daily orally for 14 days.